Poolbeg Pharma PLC (AIM:POLB) said it will present data on its drug candidate POLB 001 at a leading medical conference next month
In the lab, the asset showed promising results in preventing cytokine release syndrome (CRS), a severe inflammatory reaction seen in cancer immunotherapy with the results to be shared with the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7.
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) will present new findings from its STAT-6 siRNA programme at the Advanced Therapy Development Congress in London later on Wednesday.
The biopharmaceutical company focuses on pioneering treatments for immunology and oncology, aiming to disrupt disease processes at the genetic level.